Peter Black, MD, FACS, FRCSC, Author at Grand Rounds in Urology

Peter Black, MD, FACS, FRCSC

University of British Columbia

Vancouver, British Columbia, Canada

Dr. Peter Black is a urologic oncologist at Vancouver General Hospital, a research scientist at the Vancouver Prostate Centre, and a Professor in the Department of Urologic Sciences at the University of British Columbia (UBC). He received his undergraduate degree from UBC and his medical degree from Johannes Gutenberg University in Mainz, Germany. He completed his urologic training at the University of Washington in Seattle and a Fellowship in Urologic Oncology at MD Anderson Cancer Center in Houston, Texas. He has a clinical subspecialty interest in bladder cancer. He maintains a grant-funded translational research program in urothelial carcinoma and is an active cancer clinical trialist in this field.

Disclosures:

Talks by Peter Black, MD, FACS, FRCSC

Bladder Sparing Regimens for Muscle Invasive Disease: Should We Be Doing this More?

Posted by Peter Black, MD, FACS, FRCSC | Mar 2023

Peter Black, MD, FACS, FRCSC, discusses trimodal therapy (TMT) as a bladder-sparing option for some patients with muscle-invasive bladder cancer (MIBC).

Use of Biomarkers in NMIBC: What’s New and What Should We Use?

Posted by Peter Black, MD, FACS, FRCSC | Dec 2022

Dr. Peter C. Black moderated an insightful panel discussion exploring the latest advancements in the use of biomarkers for non-muscle invasive bladder cancer (NMIBC) and their potential integration into clinical practice.

Clinical Implications of Similarities and Differences Between Upper-Tract and Bladder Urothelial Carcinoma

Posted by Peter Black, MD, FACS, FRCSC | Feb 2020

Peter Black, MD, FACS, FRCSC, a Urologic Oncologist at Vancouver General Hospital, a Senior Research Scientist at the Vancouver Prostate Centre, and a Professor in the Department of Urologic Sciences at the University of British Columbia, examines key differences between upper-tract and bladder urothelial carcinomas, and their impact on diagnosis and treatment of each respective disease. He discusses subtle molecular differences between each disease, how these variations’ relationship to genetic alterations could lead to marker-based therapy, as well as treatments that are effective in treating both diseases.

Diagnostic Challenges with Upper-Tract Urothelial Carcinoma

Posted by Peter Black, MD, FACS, FRCSC | Feb 2020

Peter Black, MD, FACS, FRCSC, discusses questions, challenges, and methods in diagnosing upper-tract urothelial cancer. He analyzes established criteria for when to conduct a biopsy, discusses various methods and tools used for obtaining sufficient tissue for diagnosis, and how risk stratification impacts the selection of options for management of the disease.

Should Variant Histology Change Management of Bladder Cancer?

Posted by Peter Black, MD, FACS, FRCSC | Mar 2018

Peter Black, MD, FRCSC, fills in for Ashish Kamat, MD, at the 2nd annual IBCU, discussing why and how clinicians should adapt bladder cancer treatment based on variant histologies. Dr. Black identifies sub-types of bladder cancer and the way gene expression and squamous differentiation play a role in risk-stratifying the disease. He explains the proper management of each sub-type, including MD Anderson treatment algorithms for NMIBC and MIBC.